AZ announces results delay for key lung cancer trial
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
Read More
Tag: MYSTIC
Breakthrough status for AZ’ lung cancer drug Imfinzi
US regulators have granted AstraZeneca’s Imfinzi breakthrough status for the treatment of certain patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC).
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
